Skip to main content

Lisa Carey, MD, member of the UNC Lineberger Comprehensive Cancer Center, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

Lisa Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the UNC School of Medicine, was featured in a video interview on the FeDeriCa trial in HER2+ Breast Cancer. She is also deputy director of clinical sciences, division chief, Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center

Watch the video and read more about the FeDeriCa trial here.